As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Staar Surgical Co. The largest reported stake is Broadwood Partners, L.P.'s, at 32.6%. 28 filings are on record since July 29, 2025 (Schedule 13D/A, March 13, 2026).
Sell to companies like Staar Surgical Co? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: BlackRock, Inc. · Sole voting: 4,534,467 · Shared voting: 0 · Sole dispositive: 4,611,827 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-10-27
- · Reporting person: Madison Avenue International LP · Sole voting: 0 · Shared voting: 4,175,748 · Sole dispositive: 0 · Shared dispositive: 4,175,748 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Point72 Asset Management, L.P. · Percent: 5.2% · SCHEDULE 13G
- · Holder: BlackRock, Inc. · Percent: 13.1% · SCHEDULE 13G/A
- · Holder: Madison Avenue International LP · Percent: 5.8% · SCHEDULE 13G
Staar Surgical Co has 28 Schedule 13D or 13G filings on record since 2025-07-29. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Broadwood Partners, L.P. | 32.6% | 16,123,842 | SCHEDULE 13D/A, 2026-03-13 | 2026-03-13 |
| BlackRock, Inc. | 9.2% | 4,611,827 | SCHEDULE 13G/A, 2026-10-27 | 2026-09-30 |
| Madison Avenue International LP | 8.4% | 4,175,748 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| Yunqi Capital Limited | 6.5% | 3,257,130 | SCHEDULE 13D/A, 2026-01-16 | 2026-01-14 |
| Point72 Asset Management, L.P. | 5.2% | 2,591,498 | SCHEDULE 13G, 2026-05-12 | 2026-05-11 |
| Soleus Capital Master Fund, L.P. | 1% | 500,000 | SCHEDULE 13G/A, 2025-11-07 | 2025-09-30 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
| Armistice Capital, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Staar Surgical Co and the warning signs.
Free to see. No signup.
Keep reading
More on Staar Surgical Co and the records around it.
Staar Surgical Co elsewhere on the record
- Leadership changes Sep 2026
- Who owns it
Companies that share a holder
- Broadwood Partners, L.P. also filed stake reports on 2 other companies: Insight Molecular Diagnostics Inc. (Apr 2026), Lineage Cell Therapeutics, Inc. (Nov 2025)
- Madison Avenue International LP also filed stake reports on 11 other companies: Ultragenyx Pharmaceutical Inc. (Oct 2026), Graham Holdings Co (Aug 2026), Theravance Biopharma, Inc. (Aug 2026)
- Soleus Capital Master Fund, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
Watch Staar Surgical Co
Get an email when Staar Surgical Co files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Staar Surgical Co?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Staar Surgical Co: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Staar Surgical Co covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
29 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 4,534,467 | 0 | 4,611,827 | 0 | SCHEDULE 13G/A, 2026-10-27 |
| Madison Avenue International LP | 0 | 4,175,748 | 0 | 4,175,748 | SCHEDULE 13G/A, 2026-08-14 |
| Madison Avenue Partners, LP | 0 | 4,175,748 | 0 | 4,175,748 | SCHEDULE 13G/A, 2026-08-14 |
| EMAI Management, LLC | 0 | 4,175,748 | 0 | 4,175,748 | SCHEDULE 13G/A, 2026-08-14 |
| Madison Avenue GP, LLC | 0 | 4,175,748 | 0 | 4,175,748 | SCHEDULE 13G/A, 2026-08-14 |
| Caraway Jackson Investments LLC | 0 | 4,175,748 | 0 | 4,175,748 | SCHEDULE 13G/A, 2026-08-14 |
| Eli Samaha | 0 | 4,175,748 | 4,175,748 | 4,175,748 | SCHEDULE 13G/A, 2026-08-14 |
The latest filing identifies Staar Surgical Co by CUSIP 852312305 and gives its principal executive office as 25510 Commercentre Drive, Lake Forest, CA 92630 (SCHEDULE 13G/A, 2026-10-27).
What the percentages are based on
The following percentage is based on 49,788,495 Common Stock outstanding as of May 8, 2026, as disclosed in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 13, 2026. As of June 30, 2026, the Reporting Persons may be deemed to have beneficially owned approximately 8.4% of the outstanding Common Stock.Madison Avenue International LP, SCHEDULE 13G/A, 2026-08-14
Purpose of Transaction (Item 4)
Broadwood Partners, L.P.
The Reporting Persons are filing this Schedule 13D/A to report a change in their respective beneficial ownership percentages. No material changes have been made to the Reporting Persons' Item 4 disclosure in the 13D/A previously filed on January 16, 2026 (Amendment No. 43), except that Richard T. LeBuhn shall cease to be a Reporting Person immediately upon the filing of this Amendment No. 44 as a result of the termination of the Joint Filing and Solicitation Agreement described in the 13D/A previously filed on January 16, 2026 (Amendment No. 43). The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on various factors including, without limitation, the Issuer's financial position, the price levels of the Shares, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may take such actions with respect to their investment in the Issuer as they deem appropriate. In that regard, the Reporting Persons have been and may continue to be in contact with members of the Issuer's management, Board, other significant shareholders and others regarding alternatives that the Issuer could employ to create significant additional shareholder value over time. Except as otherwise set forth herein, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D. However, subject to …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-03-13; the filing has the rest
Yunqi Capital Limited
On January 14, 2026, the Issuer entered into a letter agreement (the "Cooperation Agreement") with Broadwood Partners, L.P. pursuant to which the Issuer agreed, among other things, to appoint Christopher Min Fang Wang to its Board of Directors, effective as of the date of the Cooperation Agreement.Item 4 of the SCHEDULE 13D/A filed 2026-01-16
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-29 | The Vanguard Group | 8.86% | SCHEDULE 13G/A |
| 2025-08-08 | Broadwood Partners, L.P. | 27.3% | SCHEDULE 13D/A |
| 2025-08-15 | Armistice Capital, LLC | 5.67% | SCHEDULE 13G/A |
| 2025-09-02 | Broadwood Partners, L.P. | 27.3% | SCHEDULE 13D/A |
| 2025-09-17 | Broadwood Partners, L.P. | 27.4% | SCHEDULE 13D/A |
| 2025-09-22 | Yunqi Capital Limited | 5.1% | SCHEDULE 13D |
| 2025-09-26 | Broadwood Partners, L.P. | 27.4% | SCHEDULE 13D/A |
| 2025-10-07 | Yunqi Capital Limited | 5.1% | SCHEDULE 13D/A |
| 2025-10-21 | Yunqi Capital Limited | 5.1% | SCHEDULE 13D/A |
| 2025-10-22 | Broadwood Partners, L.P. | 27.4% | SCHEDULE 13D/A |
| 2025-10-24 | Broadwood Partners, L.P. | 27.4% | SCHEDULE 13D/A |
| 2025-10-27 | Yunqi Capital Limited | 5.1% | SCHEDULE 13D/A |
| 2025-11-03 | Yunqi Capital Limited | 5.1% | SCHEDULE 13D/A |
| 2025-11-07 | Soleus Capital Master Fund, L.P. | 1% | SCHEDULE 13G/A |
| 2025-11-14 | Armistice Capital, LLC | 0% | SCHEDULE 13G/A |
| 2025-11-21 | Broadwood Partners, L.P. | 30.2% | SCHEDULE 13D/A |
| 2025-12-11 | Yunqi Capital Limited | 5.1% | SCHEDULE 13D/A |
| 2025-12-17 | Broadwood Partners, L.P. | 30.2% | SCHEDULE 13D/A |
| 2026-01-08 | Yunqi Capital Limited | 6.5% | SCHEDULE 13D/A |
| 2026-01-16 | Yunqi Capital Limited | 6.5% | SCHEDULE 13D/A |
| 2026-01-16 | Broadwood Partners, L.P. | 31.1% | SCHEDULE 13D/A |
| 2026-03-13 | Broadwood Partners, L.P. | 32.6% | SCHEDULE 13D/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-04-20 | Madison Avenue International LP | 5.8% | SCHEDULE 13G |
| 2026-04-24 | BlackRock, Inc. | 13.1% | SCHEDULE 13G/A |
| 2026-05-12 | Point72 Asset Management, L.P. | 5.2% | SCHEDULE 13G |
| 2026-08-14 | Madison Avenue International LP | 8.4% | SCHEDULE 13G/A |
| 2026-10-27 | BlackRock, Inc. | 9.2% | SCHEDULE 13G/A |
Questions about who owns Staar Surgical Co
Who owns Staar Surgical Co?
On this page, 5 holders' latest ownership filings report 5% or more of Staar Surgical Co: Broadwood Partners, L.P. (32.6%, Schedule 13D/A, filed 2026-03-13), BlackRock, Inc. (9.2%, Schedule 13G/A, filed 2026-10-27), Madison Avenue International LP (8.4%, Schedule 13G/A, filed 2026-08-14), Yunqi Capital Limited (6.5%, Schedule 13D/A, filed 2026-01-16) and Point72 Asset Management, L.P. (5.2%, Schedule 13G, filed 2026-05-12).
Who are the largest shareholders of Staar Surgical Co?
By the share each holder's latest filing reports, the largest holders of Staar Surgical Co on this page are Broadwood Partners, L.P. (32.6%), BlackRock, Inc. (9.2%) and Madison Avenue International LP (8.4%).
When did Broadwood Partners, L.P. buy into Staar Surgical Co?
The filings give report dates, not purchase dates. The earliest filing from Broadwood Partners, L.P. on this page is the Schedule 13D/A, filed 2025-08-08, reporting 27.3%; its latest, Schedule 13D/A filed 2026-03-13, reports 32.6%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 28 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Staar Surgical Co
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 6, 2026 | Leadership change: Warren Foust appointed, President and Chief Executive Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Staar Surgical Co. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.